Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel tetravalent inactivated vaccine for streptococcus suis disease

A technology of Streptococcus suis and inactivated vaccines, applied in the direction of antibacterial drugs, bacterial antigen components, etc., can solve the problems of difficulty in prevention and treatment, and achieve the effects of strong immunogenicity, broad antigen spectrum, and stable genetic properties

Active Publication Date: 2013-05-08
广东永顺生物制药股份有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, the pathogenic serogroups of Streptococcus suis that have occurred in various parts of our country are different and different, which brings certain difficulties to the prevention and treatment of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] A new type of quadrivalent inactivated vaccine for Streptococcus suis, which consists of inactivated, concentrated and passed the security inspection, and treated with a unique toxin removal technology Coccus C55914 antigen, Lambert Group E Streptococcus C55949 antigen and Streptococcus suis type 2 HA9801 antigen are prepared by mixing with adjuvant aluminum hydroxide glue.

[0028] 1. Strains

[0029] a. Streptococcus equi subspecies zooepidemicus strain C55138 of Group C of Lambert: identified, kept and supplied by the China Veterinary Drug Control Institute.

[0030] b. Streptococcus strain C55914 of Group D of Lambert: identified, kept and supplied by China Veterinary Drug Control Institute.

[0031] c. Lambert Group E Streptococcus strain C55949: identified, kept and supplied by China Veterinary Drug Control Institute.

[0032] d. Streptococcus suis type 2 HA9801 strain: identified, kept and supplied by the China Veterinary Drug Administration.

[0033] Intraven...

Embodiment 2

[0064] Vaccine Efficacy Testing

[0065] With 20 healthy susceptible pigs, each intramuscular injection of 2ml of the above-mentioned vaccine, containing 1 dose, after 21 days, the immune test pigs injected with the vaccine were divided into four groups, and the C group C55138, D group C55914, D group C55914, Group E C55949 Streptococcus virulent strain challenge and Streptococcus suis type 2 HA9801 strain. 20 pigs in the control group were equally divided into four groups, and were challenged with the four virulent streptococcus strains of C group C55138, D group C55914, E group C55949 and Streptococcus suis type 2 HA9801 strain respectively.

[0066] Streptococcus group C strain C55138: Select 5 immunized pigs, together with 5 control pigs with the same conditions, inject a lethal dose of virulent strain C55138 strain of group C, observe for 10 days, 4 / 5 of the immune pigs are protected, and the control pigs 4 / 5 or more death is qualified.

[0067] Streptococcus group D C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a novel tetravalent inactivated vaccine for streptococcus suis disease, which is prepared from a Lancefield group C streptococcus equi zooepidemicus C55138 antigen, a Lancefield group D streptococcus C55914 antigen, a Lancefield group E streptococcus C55949 antigen and a streptococcus suis type 2 HA9801 antigen by the steps of strain reproduction, bacterial liquid cultivation, pure inspection, live bacteria counting, inactivation, inactivation inspection, sedimentation and concentration, toxin removal, vaccine preparation by mixing, asepsis inspection of the vaccine, potency inspection and subpackaging. The novel tetravalent inactivated vaccine for the streptococcus suis disease can take precautions against four streptococcus suis diseases caused by Lancefield group C streptococcus, Lancefield group D streptococcus, Lancefield group E streptococcus and streptococcus suis type 2 through one-time vaccination, and has wide application prospect.

Description

technical field [0001] The invention relates to the technical field of veterinary biological products, in particular to a quadrivalent inactivated vaccine for Streptococcus suis. Background technique [0002] Streptococcus suis is a common infectious disease, which is a general term for different symptom types caused by many different groups of Streptococcus. At present, there are reports of streptococcal disease in many countries and regions, and its prevalence is on the rise. The disease is mainly characterized by causing swine septicemia, suppurative lymphadenitis, meningitis, and arthritis. Under the action of some specific inducements, the mortality rate of affected pigs can reach about 80%, which seriously threatens the development of pig industry. [0003] Since the 1960s in China, streptococcal suis has occurred successively in Guangxi, Guangdong, Fujian, Hunan, Jiangxi, Anhui, Jiangsu, Sichuan and other places. Economic losses. There are many serogroups of Strept...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/116A61K39/09A61P31/04
Inventor 杨球林旭埜张毓金游启有以体强郭沈涛王少英
Owner 广东永顺生物制药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com